| Bid | n/a |
| Market Cap | 2.84M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -28.02 |
| PE Ratio (ttm) | -0.06 |
| Forward PE | n/a |
| Analyst | Sell |
| Ask | n/a |
| Volume | 6,447 |
| Avg. Volume (20D) | 4,470 |
| Open | 1.68 |
| Previous Close | 1.68 |
| Day's Range | 1.56 - 1.68 |
| 52-Week Range | 1.37 - 9.60 |
| Beta | undefined |
About TLIS
Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19. In addition, it develops Talis One assay kit for respiratory infections, infections related to women's ...
Analyst Forecast
According to 1 analyst ratings, the average rating for TLIS stock is "Sell." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.
1 month ago · https://www.marketscreener.com
North American Morning Briefing : Global Ad Shares -2-Lundin Mining Announces Sale to Boliden of its Neves-Corvo operation in Portugal and Zinkgruvan operation in Sweden for Up to $1.52 Billion: Lundin To Receive Upfront Cash Consideration of $1.37B Upon...